Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 6/20 | 0.62 |
| ▸ | PTPRB | P23467 | 6/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10041887 | 0.87 | ABCB1 (0.64) | ABCB1PTPRBCA1CA2CA7 | |
| SCHEMBL24140416 | 0.85 | ABCB1 (0.67) | ABCB1PTPRBCA1CA2CA7 | |
| SCHEMBL28923528 | 0.85 | ABCB1 (0.67) | ABCB1PTPRBCA1CA2CA7 | |
| SCHEMBL24140388 | 0.85 | ABCB1 (0.67) | ABCB1PTPRBCA1CA2CA7 | |
| SCHEMBL24140420 | 0.85 | ABCB1 (0.62) | ABCB1PTPRBCA1CA2CA7 | |
| SCHEMBL24140870 | 0.85 | ABCB1 (0.66) | ABCB1PTPRBCA1CA2CA7 | |
| SCHEMBL25826884 | 0.85 | ABCB1 (0.66) | ABCB1PTPRBCA1CA2CA7 | |
| SCHEMBL24140376 | 0.83 | ABCB1 (0.64) | ABCB1PTPRBCA1CA2CA7 | |
| SCHEMBL24140377 | 0.83 | ABCB1 (0.64) | ABCB1PTPRBCA1CA2CA7 | |
| SCHEMBL24140864 | 0.81 | ABCB1 (0.61) | ABCB1PTPRBCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028342-A1 | ENHANCING ANTIMETASTASIS ACTIVITY USING TARGETED PROTEIN DEGRADATION | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2026-01-29 | — | — | US | disclosed |
| US-20230414775-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2023-12-28 | — | — | US | disclosed |
| WO-2023129518-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| EP-4171653-A2 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | Regeneron Pharmaceuticals, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20230069722-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230069722-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | SDCBP, TEK, TEKT1 | ABCB1 895/4885PTPRB 570/4885CA1 3635/4885 |
| US-20260028342-A1 | ENHANCING ANTIMETASTASIS ACTIVITY USING TARGETED PROTEIN DEGRADATION | EEF1A2, EEF1E1, EEF1D | ABCB1 1705/4885PTPRB 4078/4885CA1 3987/4885 |
| US-20230414775-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | SDCBP, TEK, TEKT1 | ABCB1 895/4885PTPRB 570/4885CA1 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.